These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 26812490)

  • 1. Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia.
    Zhang Y; Wu S; Luo D; Zhou J; Li D
    PLoS One; 2016; 11(1):e0147545. PubMed ID: 26812490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia.
    Zhu HH; Guo ZP; Jia JS; Jiang Q; Jiang H; Huang XJ
    Leuk Res; 2018 Feb; 65():14-19. PubMed ID: 29232592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
    Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
    Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care.
    Iland HJ; Wei A; Seymour JF
    Best Pract Res Clin Haematol; 2014 Mar; 27(1):39-52. PubMed ID: 24907016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed recovery of normal hematopoiesis in arsenic trioxide treatment of acute promyelocytic leukemia: a comparison to all-trans retinoic acid treatment.
    Shinjo K; Takeshita A; Sahara N; Kobayashi M; Nakamura S; Shigeno K; Naito K; Maekawa M; Ohnishi K; Ohno R
    Intern Med; 2005 Aug; 44(8):818-24. PubMed ID: 16157979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
    Iland HJ; Collins M; Bradstock K; Supple SG; Catalano A; Hertzberg M; Browett P; Grigg A; Firkin F; Campbell LJ; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
    Lancet Haematol; 2015 Sep; 2(9):e357-66. PubMed ID: 26685769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
    Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
    Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
    Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ;
    N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemostatic abnormalities associated with acute promyelocytic leukemia and corrective effects of all-trans-retinoic acid or arsenic trioxide treatment.
    Zhao W; Wang X; Guo W; Qu B; Wang H; Shen Z; Chen Z; Wang Z
    Chin Med J (Engl); 2000 Mar; 113(3):236-40. PubMed ID: 11775254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.
    Adès L; Thomas X; Bresler AG; Raffoux E; Spertini O; Vey N; Marchand T; Récher C; Pigneux A; Girault S; Deconinck E; Gardin C; Tournilhac O; Lambert JF; Chevallier P; de Botton S; Lejeune J; Dombret H; Chevret S; Fenaux P
    Haematologica; 2018 Dec; 103(12):2033-2039. PubMed ID: 30026341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents.
    Zhu J; Guo WM; Yao YY; Zhao WL; Pan L; Cai X; Ju B; Sun GL; Wang HL; Chen SJ; Chen GQ; Caen J; Chen Z; Wang ZY
    Leukemia; 1999 Jul; 13(7):1062-70. PubMed ID: 10400422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of combination therapy with all-trans retinoic acid and arsenic trioxide on acute promyelocytic leukemia].
    Zhang GC; Zheng D; Li QH; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Apr; 23(4):430-4. PubMed ID: 15087033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular remission without blood product support using all-trans retinoic acid (ATRA) induction and combined arsenic trioxide/ATRA consolidation in a Jehovah's Witness with de novo acute promyelocytic leukaemia.
    Kennedy GA; Marlton P; Cobcroft R; Gill D
    Br J Haematol; 2000 Dec; 111(4):1103-5. PubMed ID: 11167746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of triple-induction regimen including all-trans retinoic acid, arsenic trioxide plus anthracyclines for adults with non-high-risk acute promyelocytic leukemia].
    Ma RJ; Yuan XL; Jiang L; Yang SW; Yang J; Wang Z; Zhang P; Zhang L; Shang BJ; Cheng LN; Zhang Y; Zhu ZM
    Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(30):2387-2391. PubMed ID: 34404132
    [No Abstract]   [Full Text] [Related]  

  • 15. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
    Leu L; Mohassel L
    Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia.
    Cui W; Wang J; Nie RM; Zhao LL; Gao MQ; Zhu HM; Chen L; Hu J; Li JM; Shen ZX; Wang ZY; Chen SJ; Chen Z; Wang KK; Xi XD; Mi JQ
    Eur J Haematol; 2018 Apr; 100(4):344-350. PubMed ID: 29266395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arsenic and apoptosis in the treatment of acute promyelocytic leukemia.
    Look AT
    J Natl Cancer Inst; 1998 Jan; 90(2):86-8. PubMed ID: 9450562
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of all-trans-retinoic acid and arsenic trioxide on the hemostatic disturbance associated with acute promyelocytic leukemia.
    Zhao W; Wang H; Wang X; Wu F; Guo W; Qu B; Shen Z; Wang Z
    Thromb Res; 2001 May; 102(3):197-204. PubMed ID: 11369412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
    Quezada G; Kopp L; Estey E; Wells RJ
    Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute promyelocytic leukemia as a paradigm for targeted therapy.
    Tallman MS
    Semin Hematol; 2004 Apr; 41(2 Suppl 4):27-32. PubMed ID: 15190513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.